European Federation of Pharmaceutical Industries and Associations
Budget
€6 — €0
EP Access
14
accredited persons
Staff
34
13.4 FTE
EU Grants
None
Mission & Goals
EFPIA represents the biopharmaceutical industry operating in Europe. Through its direct membership of 37 national associations, 38 leading pharmaceutical companies, and a growing number of small and medium-sized enterprises (SMEs), EFPIA’s mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy. Our vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and better outcomes for patients. EFPIA’s activities extend to all matters of common interest to its members. In particular, it aims to foster an environment that encourages pharmaceutical research and development, manufacture in compliance with high-quality standards, intellectual property protection and the introduction of regulatory requirements to allow patients rapid access to medicinal products.
EU Legislative Interests
Any health or pharmaceutical policy stemming from the European institutions, such as - but not exclusive - Industrial Policy, Pharmaceutical Strategy, pharmaceutical, orphan and paediatrics legislation, Horizon Europe Research Programme, HTA policy, IP policy, One Health Approach to tackle AMR, COVID-19 outbreak measures. EFPIA also follows ongoing trade negotiations and legislative files relevant to the innovative pharmaceutical industry (such as Green Deal, Water Framework Directive, Welfare of animals in scientific testing etc). Main EU legislative proposals or policies targeted (a non-exhaustive list) A Pharmaceutical Strategy for Europe – over 50 legislative and non-legislative proposals • Directive 2001/83/EC on the Community code relating to medicinal products for human use • Regulation (EC) No 726/2004 of the European Parliament and of the Council laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency • Regulation (EC) No 141/2000 of the European Parliament and of the Council on orphan medicinal products. • Regulation (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use In addition, we also follow for example: • Clinical Trial Regulation • EMA Fees Regulation • Europe’s Beating Cancer Plan • European Health Data Space • HERA Regulation • SPCs Regulation revision
Communication Activities
EFPIA communications activities include: • Publishing new evidence (etc. reports, leaflets, infographics) on the policies mentioned above on efpia.eu • Drafting blog post to share opinions • Organising events including EFPIA members and external stakeholders • Disseminating our key messages through media and social media
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
BIAC British Chamber of Commerce DIA EACD EAPM ECPA EPAA - European Partnership for Alternative Approaches to Animal EPC FAIB FEAM - Federation of European Academies of Medicine Friends of Europe Kangaroo Group Patients Access Partnership TOPRA THE EUROPEAN HOUSE – AMBROSETTI
Organisation Members
EFPIA’s constituent entities include: • 38 corporate members (companies) • 37 member associations (national associations) • 16 SMEs • 31 Partners in Research http://www.efpia.eu/about-us/membership
Additional Information
According to our calculations, the declared above amount as per guidelines, is correct. The estimate of annual costs related to activities covered by the register covers personnel related expenses as well as the costs related to intermediary activities.
Commissioner Meetings
No recorded meetings with EU commissioners.